Education
About Us
Working with TipRanks
Follow Us
AlzeCure Pharma AB (DE:AC6)
:AC6
AC6 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.04 - €0.37
Previous CloseN/A
Volume0.00
Average Volume (3M)2.52K
Market Cap
€22.52M
Enterprise Value€160.44M
Total Cash (Recent Filing)€20.82M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.74
Next Earnings
Aug 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding88,295,200
10 Day Avg. Volume162
30 Day Avg. Volume2,522
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.04 and its highest was €0.37 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €22.52M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2025 which is in 68 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on May 05, 2025. The company reported -€0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.01.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 88,295,200 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.111%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
Technical Analysis
Alzinova AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
Active Biotech AB
―
NextCell Pharma AB
―